September 3, twenty-five patient organizations working in the field of HIV response in Russia published an open letter to Gilead Sciences, asking the pharmaceutical company to disclaim patent rights for the combination of tenofovir and emtricitabine, marketed under the tradename Truvada.
ITPCru team is glad to present their report on ARVs procurement monitoring in Russia in 2018.
On the way to 90: Analysis of procurement and provision of ARV drugs in seven countries of Eastern Europe and Central Asia
ITPCru is proud to present its first regional report on procurement and provision of antiretroviral drugs in 7 countries of Eastern Europe and Central Asia in 2017. The report is based on a series of national reports implemented by patient organizations in the respective countries (Armenia, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russia, Ukraine).
Treatment Preparedness Coalition in Eastern Europe and Central Asia (ITPCru) expresses its deep concern over the situation in Kazakhstan where hundreds of people for several weeks have been facing stock-outs of life-saving antiretroviral treatment.
Coverage expansion: risks and opportunities. The findings of the ARV drugs procurement monitoring in 2017
ITPCru has published their new report about the results of ARV drugs procurement monitoring in 2017.
The Association of Clinical Trials Organizations published their newsletter “Russian clinical trials market in 2012-2017”. A part about HCV, HIV and TB drugs is included.
We would like to present you our new poster in support of people with HIV who were recently diagnosed. It is called “Good news for people with HIV”. The poster contains separate blocks of information about differents aspects, for example, about a fact that effective treatment exists, people don’t die of HIV anymore, a lifespan is not limited by HIV, HIV
Assessment of HIV treatment adherence among people who use injectable drugs was performed in Kyrgyzstan. It is the first study in the country for all period of ART programmes implementation in the Kyrgyz Republic.
Exit from the labyrinth: the end of decentralization. The results of monitoring of purchases of ARV drugs in Russia in 2016
We are glad to present you the brief english version of the report “Exit from the labyrinth: the end of decentralization. The results of monitoring of purchases of ARV drugs in Russia in 2016”. The purpose of the report is to obtain conclusions based on the analysis of 4500 public procurement monitoring data for ARV drugs in 2016, and to
November 02-04 Tbilisi hosted a meeting dedicated to the issues of access to medicines in terms of the barriers associated with intellectual property. The meeting was attended by representatives from the following pharmaceutical companies: Pharmasyntez (Russia), Biocad (Russia), Cipla (India), Mylan (U.S.), Tatchempharm (Russia), and PharmEvo (Pakistan). The following issues have been discussed at the meeting: